IP Verse

Combined Pharmaceutical Composition - EP3030262

The patent EP3030262 was granted to Cytune Pharma on Oct 9, 2019. The application was originally filed on Aug 8, 2014 under application number EP14761281A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3030262

CYTUNE PHARMA
Application Number
EP14761281A
Filing Date
Aug 8, 2014
Status
Opposition Rejected
Feb 24, 2023
Publication Date
Oct 9, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONJul 9, 2020MEWBURN ELLIS -

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2009002562
INTERNATIONAL-SEARCH-REPORTWO2012175222
OPPOSITIONEP130039647
OPPOSITIONEP3030262
OPPOSITIONWO2007046006
OPPOSITIONWO2009002562
OPPOSITIONWO2012175222
OPPOSITIONWO2015018529

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- MITTICA G ET AL, "Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer?", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20160720), Database accession no. EMB-20160548250
EXAMINATION- MITTICA G ET AL, "Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer?", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20160720 MDPI AG CHE, (20160720), vol. 17, no. 7, ISSN 1661-6596
EXAMINATION- JUNZO HAMANISHI ET AL, "PD-1/PD-L1 blockade in cancer treatment: perspectives and issues", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, GB, (20160222), vol. 21, no. 3, doi:10.1007/s10147-016-0959-z, ISSN 1341-9625, pages 462 - 473, XP055535295
INTERNATIONAL-SEARCH-REPORT- MARIE VINCENT ET AL, "Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency", INTERNATIONAL JOURNAL OF CANCER, (20130801), vol. 133, no. 3, doi:10.1002/ijc.28059, ISSN 0020-7136, pages 757 - 765, XP055151554 [Y] 1-11 * page 760, column l, paragraph 3 *
INTERNATIONAL-SEARCH-REPORT- MARIE VINCENT ET AL, "CS14-6. Development of two IL15 immunocytokines targeting either GD2- or CD20- tumoral bearing cells", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 56, no. 1, doi:10.1016/J.CYTO.2011.07.396, ISSN 1043-4666, (20111001), page 102, (20110908), XP002664482 [X] 1,8-11 * abstract *
INTERNATIONAL-SEARCH-REPORT- W. XU ET AL, "Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma", CANCER RESEARCH, (20130503), vol. 73, no. 10, doi:10.1158/0008-5472.CAN-12-2357, ISSN 0008-5472, pages 3075 - 3086, XP055151674 [Y] 1-11 * the whole document * * page 4, paragraph 3 * * page 10, paragraph l *
INTERNATIONAL-SEARCH-REPORT- P. YU ET AL, "Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model", CLINICAL CANCER RESEARCH, (20101005), vol. 16, no. 24, doi:10.1158/1078-0432.CCR-10-1966, ISSN 1078-0432, pages 6019 - 6028, XP055123618 [Y] 1-11 * page 3, paragraph 3 * * page 5, paragraph 2 * * page 6, paragraph 4 *
OPPOSITION- VINCENT et al., "Tumor targeting of the IL -15 superagonist RLI by an anti- GD2 antibody strongly enhances its antitumor potency", Int J Cancer, (20130000), vol. 133, no. 3, doi:10.1002/ijc.28059, pages 757 - 765, XP055151554
OPPOSITION- XU et al., "The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody", Protein Cell, (20120000), vol. 3, no. 6, doi:10.1007/s13238-012-2044-3, pages 441 - 449, XP036359754
OPPOSITION- VINCENT et al., "CS 14-6. Development of two IL 15 immunocytokines targeting either GD2- or CD 20- tumoral bearing cells", Cytokine, (20110000), vol. 56, no. 1, doi:10.1016/j.cyto.2011.07.396, page 102, XP002664482
OPPOSITION- YU et al., "Simultaneous inhibition of two regulatory T- cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model", Proc Natl Acad Sci USA., (20120000), vol. 109, no. 16, doi:10.1073/pnas.1203479109, pages 6187 - 6192, XP055147800
OPPOSITION- MORTIER et al., "Soluble interleukin-15 receptor alpha ( IL -15R alpha)-sushi as a selective and potent agonist of IL -15 action through IL -15R beta/gamma. Hyperagonist IL -15 x IL -15R alpha fusion proteins", J Biol Chem., (20060000), vol. 281, no. 3, doi:10.1074/jbc.M508624200, pages 1612 - 1619, XP002394330
OPPOSITION- XU et al., "Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma", Cancer Res., (20130000), vol. 73, no. 10, doi:10.1158/0008-5472.CAN-12-2357, pages 3075 - 3086, XP055151674
OPPOSITION- YU et al., "Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model", Clin Cancer Res., (20100000), vol. 16, no. 24, doi:10.1158/1078-0432.CCR-10-1966, pages 6019 - 6028, XP055123618
OPPOSITION- BESSARD et al., "High antitumor activity of RLI, an interleukin-15 ( IL -15)- IL -15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer", Mol Cancer Ther., (20090000), vol. 8, no. 9, doi:10.1158/1535-7163.MCT-09-0275, pages 2736 - 2745, XP002664481
OPPOSITION- KERMER et al., "An antibody fusion protein for cancer immunotherapy mimicking IL -15 trans-presentation at the tumor site", Mol Cancer Ther., (20120000), vol. 11, no. 6, doi:10.1158/1535-7163.MCT-12-0019, pages 1279 - 1288, XP002683666

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents